Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 5344
Rating:

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Prof Gnant talks to ecancertv at ASCO 2015 about the use of adjuvant denosumab to reduce bone problems in postmenopausal women with breast cancer receiving treatment with aromatase inhibitors.

Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopaenia, osteoporosis, and fractures - but the addition of adjuvant denosumab to the treatment plan reduces patients' risk of clinical fractures.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation